| abstract |
The disclosure relates to morpholino-oxazino-purin-pyrimidin-2-amine derivatives of formula (I) having anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity, wherein the variables shown in formula (I) are as defined in the specification. Methods are described for using these tricyclic PI3K inhibitor compounds of formula (I) for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. These tricyclic compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. Exemplary compounds include: 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine and 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-[1,4]oxazino[3,4-e]purin-2-yl)-4-(trifluoromethyl)pyridyl-2-amine. |